Protective effects of the antioxidant sulforaphane on behavioral changes and neurotoxicity in mice after the administration of methamphetamine

Psychopharmacology

Volumn 222, Issue 1, 2012, Pages 37-45

  Chen, Hongxian ^a,b   Wu, Jin ^a   Zhang, Jichun ^a   Fujita, Yuko ^a   Ishima, Tamaki ^a   Iyo, Masaomi ^c   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Dopamine; Methamphetamine; Microglia; Neurotoxicity; Sensitization; Sulforaphane

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; ANTIOXIDANT; DOPAMINE; DOPAMINE TRANSPORTER; METHAMPHETAMINE; SULFORAPHANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BEHAVIOR; BEHAVIOR CHANGE; CELL ACTIVATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EXPOSURE; DRUG MECHANISM; IMMUNOREACTIVITY; LOCOMOTION; MALE; MICROGLIA; MONOTHERAPY; MOUSE; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; ANTIOXIDANTS; BASAL GANGLIA; BEHAVIOR, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; METHAMPHETAMINE; MICE; MICE, INBRED BALB C; MICROGLIA; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; THIOCYANATES;

EID: 84859996055     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2619-3     Document Type: Article

References (55)

1. Açikgöz O, Gonenc S, Gezer S et al (2001) Methamphetamine causes depletion of glutathione and an increase in oxidized glutathione in the rat striatum and prefrontal cortex. Neurotox Res 3:277-280
2. Albers DS, Sonsalla PK (1995) Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther 275:1104-1114
3. Ali SF, Newport GD, Slikker W Jr (1996) Methamphetamine-induced dopaminergic toxicity in mice. Role of environmental temperature and pharmacological agents. Ann NY Acad Sci 801:187-198
4. Barr A, Panenka W, MacEwan W et al (2006) The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci 31:301-313
5. Cadet JL, Jayanthi S, Deng X (2003) Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J 17:1775-1788
6. Cadet JL, Krasnova IN, Jayanthi S, Lyles J (2007) Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox Res 11:183-202
7. Chen HX, Wu J, Zhang JC, Hashimoto K (2010) Recent topics on pharmacotherapy for amphetamine-type stimulants abuse and dependence. Curr Drug Abuse Rev 3:222-238
8. Cheung KL, Kong AN (2010) Molecular targets of dietary phenylethyl isothiocyanate and sulforaphane for cancer chemoprevention. AAPS J 12:87-97
9. Colfax G, Santos GM, Chu P et al (2010) Amphetamine-group substances and HIV. Lancet 376:458-474
10. Danilov CA, Chandrasekaran K, Racz J, Soane L, Zielke C, Fiskum G (2009) Sulforaphane protects astrocytes against oxidative stress and delayed death caused by oxygen and glucose deprivation. Glia 57:645-656
11. Davidson C, Gow AJ, Lee TH, Ellinwood EH (2001) Methamphetamine neutoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Rev 6:1-22 (Pubitemid 32763126)
12. Escubedo E, Guitart L, Sureda FX et al (1998) Microgliosis and down-regulation of adenosine transporter induced by methamphetamine in rats. Brain Res 814:120-126 (Pubitemid 29023417)
13. Fenwick GR, Heaney RK, Mullin WJ (1983) Glucosinolates and their breakdown products in food and food plants. Crit Rev Food Sci Nutr 18:123-201
14. Fukami G, Hashimoto K, Koike K, Okamura N, Shimizu E, Iyo M (2004) Effect of antioxidant N-acetyl-L-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine. Brain Res 1016:90-95 (Pubitemid 38834276)
15. Gonzales R, Mooney L, Rawson RA (2010) The methamphetamine problem in the United States. Annu Rev Public Health 31:385-398
16. Guilarte TR, Nihei MK, McGlothan JL, Howard AS (2003) Methamphetamine induced deficits of brain monoaminergic neuronal markers: distal axotomy or neuronal plasticity. Neuroscience 122:499-513 (Pubitemid 37410176)
17. Hagiwara H, Iyo M, Hashimoto K (2009) Mithramycin protects against dopaminergic neurotoxicity in the mouse brain after administration of methamphetamine. Brain Res 1301:189-196
18. Han JM, Lee YJ, Lee SY et al (2007) Protective effect of sulforaphane against dopaminergic cell death. J Pharmacol Exp Ther 321:249-256
19. Hashimoto K (2007) New research on methamphetamine abuse. In: Toolaney GH (ed) New research on methamphetamine abuse. NovaScience, New York, pp 1-51
20. Hashimoto K, Tsukada H, Nishiyama S et al (2004) Protective effects of N-acetyl-L-cysteine on the reduction of dopamine transporters in the striatum of monkeys treated with methamphetamine. Neuropsychopharmacology 29:2018-2023 (Pubitemid 39486553)
21. Hashimoto K, Tsukada H, Nishiyama S, Fukumoto D, Kakiuchi T, Iyo M (2007) Protective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methamphetamine: a PET study in conscious monkeys. Biol Psychiatry 61:577-581 (Pubitemid 46328849)
22. Innamorato NG, Rojo AI, Garcia-Yagüe AJ, Yamamoto M, de Ceballos ML, Cuadrado A (2008) The transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol 181:680-689
23. Itoh K, Tong KI, Yamamoto M (2004) Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. Free Radic Biol Med 36:1208-1213 (Pubitemid 38526314)
24. Jazwa A, Rojo AI, Innamorato NG, Hesse M, Fernández-Ruiz J, Cuadrado A (2011) Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antioxid Redox Signal 14:2347-2360
25. Juge N, Mithen RF, Traka M (2007) Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci 64:1105-1127 (Pubitemid 46684547)
26. Kang KW, Lee SJ, Kim SG (2005) Molecular mechanism of nrf2 activation by oxidative stress. Antioxid Redox Signal 7:1664-1673 (Pubitemid 41768000)
27. Kita T, Paku S, Takahashi M, Kubo K, Wagner GC, Nakashima T (1998) Methamphetamine-induced neurotoxicity in BALB/c, DBA/2 N and C57BL/6 N mice. Neuropharmacology 37:1177-1784
28. Koike K, Hashimoto K, Fukami G et al (2005) The immunophilin ligand FK506 protects against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum. Neuropharmacology 48:391-397 (Pubitemid 40250002)
29. Kwak MK, Kensler TW (2010) Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol 244:66-76
30. LaVoie MJ, Card JP, Hastings TG (2004) Microglia activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp Neurol 187:47-57 (Pubitemid 38470011)
31. Licata SC, Pierce RC (2003) The roles of calcium/calmodulin-dependent and Ras/mitogen-activated protein kinases in the development of psychostimulant-induced behavioral sensitization. J Neurochem 85:14-22 (Pubitemid 36389691)
32. Miyazaki I, Asanuma M, Diaz-Corrales FJ et al (2006) Methamphetamine- induced dopaminergic neurotoxicity is regulated by quinone formation-related molecules. FASEB J 20:571-573 (Pubitemid 46671253)
33. National Institute on Drug Abuse (2002) Research report series - methamphetamine abuse and addiction. NIDA, Rockville
34. Pierce RC, Kalivas PW (1997) A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Rev 25:192-216 (Pubitemid 27501800)
35. Ping Z, Liu W, Kang Z et al (2010) Sulforaphane protects brains against hypoxic-ischemic injury through induction of Nrf2-dependent phase 2 enzyme. Brain Res 1343:178-185
36. Pubill D, Canudas AM, Pallas M, Camins A, Camarasa J, Escubedo E (2003) Different glial response to methamphetamine- and methylenedioxymethamphetamine- induced neurotoxicity. Naunyn Schmiedebergs Arch Pharmacol 367:490-499 (Pubitemid 36718300)
37. Robinson TE, Becker JB (1986) Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 396:157-198 (Pubitemid 16100809)
38. Scholl JL, Feng N, Watt MJ, Renner KJ, Forster GL (2009) Individual differences in amphetamine sensitization, behavior and central monoamines. Physiol Behav 96:493-504
39. Seiden LS, Sabol KE, Ricaurte GA (1993) Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 33:639-677 (Pubitemid 23116021)
40. Sekine Y, Iyo M, Ouchi Y et al (2001) Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158:1206-1214 (Pubitemid 32717692)
41. Siebert A, Desai V, Chandrasekaran K, Fiskum G, Jafri MS (2009) Nrf2 activators provide neuroprotection against 6-hydroxydopamine toxicity in rat organotypic nigrostriatal cocultures. J Neurosci Res 87:1659-1669
42. Thomas DM, Kuhn DM (2005) Attenuated microglial activation mediates tolerance to the neurotoxic effects of methamphetamine. J Neurochem 92:790-797 (Pubitemid 40229550)
43. Thomas DM, Walker PD, Benjamins JA, Geddes TJ, Kuhn DM (2004) Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglia activation. J Pharmacol Exp Ther 311:1-7 (Pubitemid 39287777)
44. Ujike H, Sato M (2004) Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann NY Acad Sci 1025:279-287 (Pubitemid 39643873)
45. United Nations Office on Drug Use and Crime (UNODC) (2008) World drug report. UNODC, Vienna
46. Vanderschuren LJ, Kalivas PW (2000) Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology (Berl) 151:99-120 (Pubitemid 30646415)
47. Volkow ND, Chang L, Wang GJ et al (2001) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158:377-382 (Pubitemid 32205193)
48. White FJ, Kalivas PW (1998) Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depend 51:141-153 (Pubitemid 28353762)
49. Wilson JM, Kalansinsky KS, Levey AI et al (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2:699-703 (Pubitemid 26191961)
50. Yamamoto J (2004) Recent trends of drug abuse in Japan. Ann NY Acad Sci 1025:430-438
51. Yamamoto BK, Raudensky J (2008) The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse. J Neuroimmune Pharmacol 3:203-217
52. Yanaka A (2011) Sulforaphane enhances protection and repair of gastric mucosa against oxidative stress in vitro, and demonstrates anti-inflammatory effects on Helicobacter pylori-infected gastric mucosae in mice and human subjects. Curr Pham Des 17:1532-1540
53. Yanaka A, Fahey JW, Fukumoto A et al (2009) Dietary sulforaphanerich broccoli sprouts reduce colonization and attenuate gastritis in Helicobacter pylori-infected mice and humans. Cancer Prev Res (Phila) 2:353-260
54. Zhang Y, Li J, Tang L (2005) Cancer-preventive isothiocyanates: dichotomous modulators of oxidative stress. Free Radic Biol Med 38:70-77 (Pubitemid 39626910)
55. Zhang L, Kitaichi K, Fujimoto Y et al (2006) Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog Neuro-Psychopharmacol Biol Psychiatry 30:1381-1393 (Pubitemid 44634942)